733 related articles for article (PubMed ID: 27294525)
1. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.
Weiskopf K; Jahchan NS; Schnorr PJ; Cristea S; Ring AM; Maute RL; Volkmer AK; Volkmer JP; Liu J; Lim JS; Yang D; Seitz G; Nguyen T; Wu D; Jude K; Guerston H; Barkal A; Trapani F; George J; Poirier JT; Gardner EE; Miles LA; de Stanchina E; Lofgren SM; Vogel H; Winslow MM; Dive C; Thomas RK; Rudin CM; van de Rijn M; Majeti R; Garcia KC; Weissman IL; Sage J
J Clin Invest; 2016 Jul; 126(7):2610-20. PubMed ID: 27294525
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy targeting the CD47/SIRPα axis.
Weiskopf K
Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
[TBL] [Abstract][Full Text] [Related]
3. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
4. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
[TBL] [Abstract][Full Text] [Related]
5. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
6. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis.
Zhang W; Huang Q; Xiao W; Zhao Y; Pi J; Xu H; Zhao H; Xu J; Evans CE; Jin H
Front Immunol; 2020; 11():18. PubMed ID: 32082311
[TBL] [Abstract][Full Text] [Related]
7. Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma.
Zhang X; Chen W; Fan J; Wang S; Xian Z; Luan J; Li Y; Wang Y; Nan Y; Luo M; Li S; Tian W; Ju D
Carcinogenesis; 2018 May; 39(5):689-699. PubMed ID: 29538621
[TBL] [Abstract][Full Text] [Related]
8. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
9. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
10. NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer.
Wang LL; Wan XY; Wang TL; Liu CQ; Zheng FM
Med Oncol; 2022 Oct; 39(12):254. PubMed ID: 36224405
[TBL] [Abstract][Full Text] [Related]
11. Macrocyclic Peptide-Mediated Blockade of the CD47-SIRPα Interaction as a Potential Cancer Immunotherapy.
Hazama D; Yin Y; Murata Y; Matsuda M; Okamoto T; Tanaka D; Terasaka N; Zhao J; Sakamoto M; Kakuchi Y; Saito Y; Kotani T; Nishimura Y; Nakagawa A; Suga H; Matozaki T
Cell Chem Biol; 2020 Sep; 27(9):1181-1191.e7. PubMed ID: 32640189
[TBL] [Abstract][Full Text] [Related]
12. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
13. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy.
Zhu H; Leiss L; Yang N; Rygh CB; Mitra SS; Cheshier SH; Weissman IL; Huang B; Miletic H; Bjerkvig R; Enger PØ; Li X; Wang J
Oncotarget; 2017 Feb; 8(7):12145-12157. PubMed ID: 28076333
[TBL] [Abstract][Full Text] [Related]
14. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
15. Targeting HDAC6 improves anti-CD47 immunotherapy.
Gracia-Hernandez M; Yende AS; Gajendran N; Alahmadi Z; Li X; Munoz Z; Tan K; Noonepalle S; Shibata M; Villagra A
J Exp Clin Cancer Res; 2024 Feb; 43(1):60. PubMed ID: 38414061
[TBL] [Abstract][Full Text] [Related]
16. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
Hao Y; Zhou X; Li Y; Li B; Cheng L
Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
[TBL] [Abstract][Full Text] [Related]
17. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
18. Anticancer efficacy of monotherapy with antibodies to SIRPα/SIRPβ1 mediated by induction of antitumorigenic macrophages.
Sakamoto M; Murata Y; Tanaka D; Kakuchi Y; Okamoto T; Hazama D; Saito Y; Kotani T; Ohnishi H; Miyasaka M; Fujisawa M; Matozaki T
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34949714
[TBL] [Abstract][Full Text] [Related]
19. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
20. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
